Skip to Content

ASH 2023: ELEVATE-TN Study – 6-Year Follow-up of Acalabrutinib Efficacy in CLL

The ELEVATE-TN study offers compelling long-term data on acalabrutinib’s effectiveness in treating chronic lymphocytic leukemia, showcasing sustained benefits and safety over 74.5 months.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top